Eric Curtis

Operates as a biopharmaceutical research and development oncology company

Operates as a biopharmaceutical company that develops novel therapeutics to address significant unmet medical needs in acute care markets

Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases

Functions as a College/University

Functions as a College/University

Provides medical care, and animal health care services

Founded in 1949, Centurion BioPharma Corp. is a Turkish pharmaceutical and American biopharmaceutical company specializing in sterile injectable products, blood products, vaccines, biosimilars, and biotechnological treatments, with a focus on rare diseases and chronic conditions. The company is based in DE. The company operates a state-of-the-art, EU GMP-certified manufacturing facility and maintains robust in-house R&D capabilities, including advanced laboratories and a skilled scientific team developing innovative generic drugs, biosimilars, and high value-added pharmaceuticals. Centurion collaborates through joint R&D, technology transfer, and licensing agreements to expand its product portfolio and market presence both domestically and internationally, including submissions for EU and other market authorizations. The company provides pharmacovigilance services aligned with national and EU regulations to monitor drug safety and efficacy and actively combats illegal and counterfeit sales of its products. Centurion BioPharma also focuses on the development of personalized medicine for solid tumor treatment, utilizing its LADR™ (Linker Activated Drug Release) technology to deliver anti-cancer therapies that target tumors more precisely.